Clinical Trial Results:
A Randomized, Double-Blind, Multi-Center Phase 2 Trial of Exemestane (Aromasin®)
plus Dasatinib versus Exemestane plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer after Disease Progression on a Non-steroidal Aromatase Inhibitor (NSAI).
+ Administrative Letter 1 dated 18-Aug-2008.
Summary
|
|
EudraCT number |
2008-003183-19 |
Trial protocol |
FR IE CZ IT SE ES GB |
Global completion date |
30 Dec 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
CA180-261_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.